Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P W H I Parren

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Biosensors & Bioelectronics|September 3, 2016
A novel label-free cell-based assay technology using biolayer interferometryD Verzijl, T Riedl, P W H I Parren, et al.
Blood Cancer Journal|July 26, 2012
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapiesM S van der Veer, M de Weers, B van Kessel, et al.
Archives of Dermatological Research|November 9, 2006
In situ depletion of CD4+ T cells in human skin by ZanolimumabL S Villadsen, L Skov, T N Dam, et al.
Scandinavian Journal of Immunology|July 15, 2017
CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma CellsM Peipp, D Wesch, H-H Oberg, et al.
Leukemia|October 19, 2011
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicityC Kellner, D Hallack, P Glorius, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
Journal of Immunological Methods|July 16, 2011
Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate developmentC Kellner, W K Bleeker, J J Lammerts van Bueren, et al.
Journal of Autoimmunity|June 24, 2025
Post-translationally modified proteins bind and activate complement with implications for cellular uptake and autoantibody formationM D van den Beukel, L Zhang, S van der Meulen, et al.
Clinical and Experimental Immunology|December 20, 2019
Carbamylation reduces the capacity of IgG for hexamerization and complement activationR Lubbers, S C Oostindie, D J Dijkstra, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Biosensors & Bioelectronics|September 3, 2016
A novel label-free cell-based assay technology using biolayer interferometryD Verzijl, T Riedl, P W H I Parren, et al.
Blood Cancer Journal|July 26, 2012
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapiesM S van der Veer, M de Weers, B van Kessel, et al.
Archives of Dermatological Research|November 9, 2006
In situ depletion of CD4+ T cells in human skin by ZanolimumabL S Villadsen, L Skov, T N Dam, et al.
Scandinavian Journal of Immunology|July 15, 2017
CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma CellsM Peipp, D Wesch, H-H Oberg, et al.
Leukemia|October 19, 2011
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicityC Kellner, D Hallack, P Glorius, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
Journal of Immunological Methods|July 16, 2011
Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate developmentC Kellner, W K Bleeker, J J Lammerts van Bueren, et al.
Journal of Autoimmunity|June 24, 2025
Post-translationally modified proteins bind and activate complement with implications for cellular uptake and autoantibody formationM D van den Beukel, L Zhang, S van der Meulen, et al.
Clinical and Experimental Immunology|December 20, 2019
Carbamylation reduces the capacity of IgG for hexamerization and complement activationR Lubbers, S C Oostindie, D J Dijkstra, et al.
Pageof 1